Click on image to view larger version.

Figure 3 (A) Proteasome 20S (x1,000) and ubiquitin (x630) by immunohistochemistry in asymptomatic, placebo-treated, and rosiglitazone-treated symptomatic plaques. Similar regions of the plaque are shown (boxes, x200). These results are typical of asymptomatic, placebo-treated, and rosiglitazone-treated symptomatic plaques. (B) Levels of proteasome 20S by specific SDS activation kit, ubiquitin levels by enzyme-linked immunosorbent assay kit *p < 0.05 compared with placebo group. p < 0.05 compared with rosiglitazone group.